Bleximenib

DRUG5 trials

Sponsors

Janssen Research & Development, LLC, Stichting Hemato-Oncologie voor Volwassenen Nederland

Conditions

Acute LeukemiaAcute LeukemiasAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaLeukemia, Myeloid, Acute

Phase 1

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

RecruitingNCT04811560

Janssen Research & Development, LLCAcute Leukemia

Start: 2021-05-19End: 2030-09-22Target: 420Updated: 2026-05-08

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Active, not recruitingNCT05453903

Janssen Research & Development, LLCLeukemia, Myeloid, Acute

Start: 2022-10-04End: 2027-03-03Updated: 2026-05-08

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

RecruitingNCT07295951

Janssen Research & Development, LLCAcute Leukemias, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia

Start: 2025-11-18End: 2026-07-13Target: 10Updated: 2026-05-08

Phase 3

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

RecruitingNCT06852222

Janssen Research & Development, LLCLeukemia, Myeloid, Acute

Start: 2025-06-04End: 2029-08-15Target: 600Updated: 2026-05-08

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

RecruitingNCT07223814

Stichting Hemato-Oncologie voor Volwassenen NederlandAcute Myeloid Leukemia

Start: 2026-03-01End: 2033-12-01Target: 875Updated: 2026-04-06

Related Papers

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Blood2025-11-031 citations

Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)

Blood2025-11-031 citations

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Blood2025-11-031 citations

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Blood2025-11-031 citations

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with <i>KMT2A</i> and <i>NPM1</i> Alterations

Blood2024-11-0524 citations

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with <i>KMT2Ar</i> or <i>NPM1</i> Alterations

Blood2024-11-0520 citations

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias

Blood2024-06-2143 citations

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring <i>KMT2A</i> or <i>NPM1</i> Alterations

Blood2023-11-0241 citations

Preclinical Efficacy of the Menin-KMT2A Inhibitor JNJ-75276617 in Combination with Venetoclax and Azacitidine in AML

Blood2023-11-023 citations

Abstract 3457: Characterization of acquired resistance mutations to menin inhibitors

Cancer Research2023-04-049 citations

Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia

Blood2022-11-1515 citations